Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

Acta Oncologica

Volumn 46, Issue 5, 2007, Pages 697-701

  Pfeiffer, Per ^a   Nielsen, Dorte ^b   Yilmaz, Mette ^c   Iversen, Anja ^a   Vejlø, Christian ^c   Jensen, Benny Vittrup ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CAPECITABINE; CETUXIMAB; DIPHENHYDRAMINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID; GRANISETRON; IRINOTECAN; OXALIPLATIN; PREDNISOLONE; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DENMARK; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG TREATMENT FAILURE; EXPERIMENTAL STUDY; FATIGUE; FEMALE; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH PROGRAM; HUMAN; INFECTION; INJECTION SITE REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY;

EID: 34249722420     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601009455     Document Type: Article

References (19)

1. Ragnhammar P, Hafström L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
2. Meyerhardt JA, Mayer RJ. Therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
3. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
4. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a Phase III Trial. J Clin Oncol 2003;21:2059-69.
5. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse. Sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
6. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004;22:4701-9.
7. Nygren P, Sørbye H, .Österlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
8. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
9. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Annual meeting of the American Society of Clinical Oncology 2001;20:A7.
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004;351:337-45.
11. European Medicines Agency (EMEA) 2004. Report No: EMEA/H/C/558.
12. Brasholt M, von der Maase H, Hansen HH. Experience from a national programme for second opinion and experimental treatment. Ann Oncol 2004;15(Suppl 3):146 (Abstract 550).
13. Sørbye H, Glimelius B, Berglund A° , Fokstuen T, Tveit KM, Brændengen M, et al. Multicentre phase II study of oxaliplatin combined with Nordic 5-fluorouracil/leucovorin bolus schedule (FLOX) as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-8.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
15. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
16. Schrag D. The price tag on progress - Chemotherapy for colorectal cancer. NEJM 2004;351:317-9.
17. Vincenzi B, Santini D, Rabitti D, Coppola R, Beomonte Zobel B, Trodella L, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. Br J Cancer 2006;94:792-7.
18. Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: A phase II study. Anticancer Res 2003;23:2981-5.
19. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: A phase II study. Cancer Chemother Pharmacol 2005;56:10-4.